Project Oncology
563 FOLLOWERS
Project Oncology presents a wide array of oncology topics designed to educate and enlighten practitioners on late-breaking discoveries, novel treatment options, evolving methods of patient management, and more. This series provides cutting-edge updates on cancer biology, diagnosis, and multidisciplinary management, as well as evidence-based recommendations to achieve optimal patient outcomes.
Project Oncology
5h ago
Guest: Justin Arnall, PharmD, BCOP, CPP
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jerry L. Spivak MD, MACP
After assessing the severity of anemia in patients with myelofibrosis, it’s important to work with them to select the best intervention. Having a personalized approach to treatment and management could have a beneficial impact on the overall quality of life of your patient. Tune in with Dr. Charles Turck for insights and experiences from real-life patient cases with Dr. Justin Arnal, Clinical Coordinator of Hematology at Atrium Health Specialty Pharmacy Service in Charlotte, North C ..read more
Project Oncology
5h ago
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Prithviraj Bose, MD
Normally, when a patient is newly diagnosed with myelofibrosis, the anemia is from the disease. And it’s important to treat these patients with an individualized treatment plan as this could have a significant positive impact on their quality of life and outcome. To learn more, dive in with Dr. Charles Turck as he speaks with Dr. Prithvi Bose, Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center ..read more
Project Oncology
3d ago
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Prithviraj Bose, MD
Normally, when a patient is newly diagnosed with myelofibrosis, the anemia is from the disease. And it’s important to treat these patients with an individualized treatment plan as this could have a significant positive impact on their quality of life and outcome. To learn more, dive in with Dr. Charles Turck as he speaks with Dr. Prithvi Bose, Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center ..read more
Project Oncology
3d ago
Host: Jennifer Caudle, DO
Guest: Jason Tremblay
Due to a high prevalence of anemia in myelofibrosis, significant challenges could occur when diagnosing patients. But making a timely and accurate diagnosis is key, along with ensuring we’re using the best therapeutic strategies. Learn more with Dr. Jennifer Caudle as she speaks with Dr. Douglas Tremblay, Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai ..read more
Project Oncology
1w ago
Host: Jennifer Caudle, DO
Guest: Jason Tremblay
Myelofibrosis is a heterogeneous disease and different hematologic manifestations, like anemia and thrombocytopenia, are variable based on the patients themselves. It might even be rare to see patients who experience myelofibrosis the same. So to take a deep dive into the treatment paradigm of this disease is Dr. Jennifer Caudle who will be speaking with Dr. Douglas Tremblay, Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai ..read more
Project Oncology
2w ago
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Tara Graff, DO, MS
The therapeutic landscape for relapsed or refractory B-cell lymphoma has greatly evolved in the past several years, with CAR T-cell therapy and personalized care becoming increasingly important in the second-line setting. Joining Dr. Charles Turck to discuss how CAR T-cell therapy and patient-centered care can help optimize outcomes in the second-line treatment of patients with B-cell lymphoma is medical oncologist Dr. Tara Graff ..read more
Project Oncology
2w ago
Host: Jennifer Caudle, DO
Guest: Sarah Rutherford, MD
Due to its strong response rates and manageable adverse events, CAR T-cell therapy is now considered the standard-of-care treatment for B-cell lymphomas in the second-line setting, which could lead to better outcomes for patients. Learn more about the efficacy and safety profile of CAR T-cell therapy with Dr. Jennifer Caudle and Dr. Sarah Rutherford, Assistant Professor of Medicine in the Division of Hematology-Oncology at Weill Cornell Medicine ..read more
Project Oncology
2w ago
Guest: Matthew Lunning, DO, FACP
It’s not uncommon for patients with B-cell lymphoma to have relapsed or refractory disease, making it essential to know how to approach their second-line treatment. Unfortunately, many challenges and unmet needs exist in this setting, which is why Dr. Matthew Lunning is here to discuss those challenges as well as the novel therapies that are helping us overcome them. Dr. Lunning is an Associate Professor in the Division of Hematology and Oncology at the University of Nebraska Medical Center ..read more
Project Oncology
1M ago
Guest: Alan Bryce, MD
Lutetium-177and radium-223 have both been shown to significantly improve survival in patients with metastatic castration-resistant prostate cancer, but how do these treatment options compare? Find out with Dr. Alan Bryce, who presented a session on this exact topic at the 2024 ASCO Genitourinary Cancers Symposium ..read more
Project Oncology
2M ago
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Neeraj Agarwal, MD, FASCO
TALAPRO-2 was a recent phase 3 study conducted in the first-line metastatic castration-resistant prostate cancer (mCRPC) setting. Patients were randomized to receive either enzalutamide plus talazoparib or enzalutamide plus placebo, and the researchers found that there was a 37 percent reduction in risk of progression or death among those who received enzalutamide plus talazoparib. Dive further into the findings and their implications for patients with mCRPC with Dr. Charles Turck and Dr. Neeraj Agarwal, Professor of Med ..read more